Protherics PLC Signs ReGel(TM) Licensing Agreement With Myungmoon Pharm

London, UK; Brentwood, TN, US; 25 September 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics' novel proprietary local, sustained release drug delivery system ReGel(TM).